ClinicalTrials.gg

Program

troculeucel

Also written as “SNK01”, “SNK01 (Super Natural Killer Cells 01)” and “Study Product: SNK01”.

Its studies are mostly in Alzheimer Disease · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Carcinoma, Non-Small-Cell Lung · Psoriasis, led by 2 companies.

Furthest: phase 2, since Oct 18, 20217 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
NKGen Biotech62 open or runningphase 2since Oct 18, 2021Mar 6, 2019Mar 2028phase 2 · NCT06189963
NKMAX10 open or runningphase 2since Apr 21, 2021Apr 21, 2021none ahead

Also a collaborator on its studies: affimed-gmbh.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2019First study: phase 1 study in Plaque PsoriasisNew to NKGen BiotechNKGen Biotech · NCT03894579 · 9 enrolled · Mexico
  2. May 3, 2019Phase 1 study in NeoplasmsNKGen Biotech · NCT03941262 · 27 enrolled · United States
  3. Dec 9, 2020Phase 1 study in Alzheimer DiseaseNKGen Biotech · NCT04678453 · 10 enrolled · Mexico
  4. Apr 21, 2021NKMAX's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to NKMAXNKMAX · NCT04872634 · 24 enrolled · Korea, Republic of
  5. Oct 18, 2021Phase 2 study in Squamous Cell Carcinoma of Head and NeckNKGen Biotech · NCT05099549 · 11 enrolled · United States
  6. Dec 6, 2023Phase 2 study in Moderate Alzheimer DiseaseNKGen Biotech · NCT06189963 · 36 planned · United States, Canada
  7. Nov 12, 2025Phase 2 study in Alzheimer DiseaseNKGen Biotech · NCT07228078 · 30 planned · United States

Ahead

  1. Mar 2028Primary completion: phase 2 study in Moderate Alzheimer DiseaseNKGen Biotech · NCT06189963
  2. Apr 2028Primary completion: phase 2 study in Alzheimer DiseaseNKGen Biotech · NCT07228078

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07228078Alzheimer Disease · United States2RecruitingNKGen BiotechApr 202830
NCT06189963Moderate Alzheimer Disease · United States, Canada2RecruitingNKGen BiotechMar 202836
NCT05099549Squamous Cell Carcinoma of Head and Neck · United States2TerminatedNKGen BiotechSep 21, 202311
NCT04872634Carcinoma, Non-Small-Cell Lung · Korea, Republic of2UNKNOWNNKMAXMay 26, 202324
NCT04678453Alzheimer Disease · Mexico1TerminatedNKGen BiotechAug 16, 202310
NCT03941262Neoplasms · United States1CompletedNKGen BiotechFeb 17, 202327
NCT03894579Plaque Psoriasis · Mexico1CompletedNKGen BiotechDec 3, 20199

How it is read

Names in the registry

  • “SNK01”, 5 entries
  • “SNK01 (Super Natural Killer Cells 01)”, 1 entry
  • “Study Product: SNK01”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
troculeucel (NKGen Biotech): development program | ClinicalTrials.gg